*The following content is generated by AI and is for reference only.
Osimertinib, marketed under the brand name Tagrisso, is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) widely recognized for its transformative impact in the treatment of non-small cell lung cancer (NSLC). Its molecular formula is C31H37ClFN5O2, and it carries the CAS registry number 984465-06-5. This compound represents a significant advancement over earlier generation TKIs due to its unique ability to selectively target EGFR mutations, including the T790M resistance mutation that often develops after initial therapy with first- or second-generation agents like gefitinib or erlotinib.
The primary clinical indication for Osimertinib is the treatment of adult patients with metastatic NSCLC whose tumors harbor specific EGFR exon 19 deletions or exon 21 L858R substitution mutations. It is also approved as an adjuvant therapy for completely resected stage IB-IIIA EGFR-mutant NSCLC to reduce the risk of recurrence. Furthermore, it serves as a first-line treatment option for patients with metastatic disease carrying these sensitizing mutations. Unlike previous inhibitors, Osimertinib demonstrates superior selectivity for mutant EGFR while sparing wild-type EGFR, which significantly reduces cutaneous toxicity such as rash and diarrhea. Additionally, its optimized pharmacokinetic profile allows for better penetration into the central nervous system, making it highly effective against brain metastases, a common complication in advanced lung cancer.
Administered orally once daily, Osimertinib functions by irreversibly binding to the ATP-binding pocket of the EGFR kinase domain, thereby inhibiting downstream signaling pathways that drive tumor cell proliferation and survival. Clinical trials have consistently demonstrated improved progression-free survival and overall survival rates compared to standard-of-care therapies. As a cornerstone in precision oncology, Osimertinib has set a new benchmark for treating EGFR-driven malignancies, offering hope to patients who previously faced limited therapeutic options upon developing resistance to prior treatments.